Castrate Sensitive Prostate Cancer
Oncology
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
3 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| goserelin | KYNTRA BIO INC. (KYNB) |
Phase 2(1)
| Drug | Company |
|---|---|
| 18F-DCFPyL | KYNTRA BIO INC. (KYNB) |
Preclinical(1)
| Drug | Company |
|---|---|
| pnt2001 | POINT Biopharma Global Inc. (PNT) |
Compare drugs
Frequently asked questions
How many drugs are in development for Castrate Sensitive Prostate Cancer?
BioSniper tracks 3 drugs in development for Castrate Sensitive Prostate Cancer across 2 companies.
How many clinical trials target Castrate Sensitive Prostate Cancer?
There are 2 clinical trials targeting Castrate Sensitive Prostate Cancer tracked by BioSniper.
What is the prevalence of Castrate Sensitive Prostate Cancer?
The estimated prevalence of Castrate Sensitive Prostate Cancer is approximately 256.0 per 100,000 population.
Deep-dive into Castrate Sensitive Prostate Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis